Friedreich's ataxia: Clinical pilot trial with recombinant human erythropoietin

被引:91
作者
Boesch, Sylvia
Sturm, Brigitte
Hering, Sascha
Goldenberg, Hans
Poewe, Werner
Scheiber-Mojdehkar, Barbara
机构
[1] Med Univ Vienna, Dept Med Chem, A-1090 Vienna, Austria
[2] Innsbruck Med Univ, Dept Neurol, Innsbruck, Austria
关键词
D O I
10.1002/ana.21177
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To determine the role of recombinant human erythropoietin as a possible treatment option in Friedreich's ataxia, we performed an open-label clinical pilot study. Primary outcome measure was the change of frataxin levels at week 8 versus baseline. Twelve Friedreich's ataxia patients received 5,000 units recombinant human erythropoietin three times weekly subcutaneously. Frataxin levels were measured in isolated lymphocytes by enzyme-linked immunosorbent assay. In addition, urinary 8-hydroxydeoxyguanosine and serum peroxides, were measured. Treatment with recombinant human erythropoietin showed a persistent and significant increase in frataxin levels after 8 weeks (p < 0.01). All patients showed a reduction of oxidative stress markers.
引用
收藏
页码:521 / 524
页数:4
相关论文
共 20 条
[1]   An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection [J].
Bogoyevitch, MA .
CARDIOVASCULAR RESEARCH, 2004, 63 (02) :208-216
[2]   Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury [J].
Brines, ML ;
Ghezzi, P ;
Keenan, S ;
Agnello, D ;
de Lanerolle, NC ;
Cerami, C ;
Itri, LM ;
Cerami, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (19) :10526-10531
[3]   Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation [J].
Calapai, G ;
Marciano, MC ;
Corica, F ;
Allegra, A ;
Parisi, A ;
Frisina, N ;
Caputi, AP ;
Buemi, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 401 (03) :349-356
[4]   Friedreich's ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion [J].
Campuzano, V ;
Montermini, L ;
Molto, MD ;
Pianese, L ;
Cossee, M ;
Cavalcanti, F ;
Monros, E ;
Rodius, F ;
Duclos, F ;
Monticelli, A ;
Zara, F ;
Canizares, J ;
Koutnikova, H ;
Bidichandani, SI ;
Gellera, C ;
Brice, A ;
Trouillas, P ;
DeMichele, G ;
Filla, A ;
DeFrutos, R ;
Palau, F ;
Patel, PI ;
DiDonato, S ;
Mandel, JL ;
Cocozza, S ;
Koenig, M ;
Pandolfo, M .
SCIENCE, 1996, 271 (5254) :1423-1427
[5]   Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes [J].
Campuzano, V ;
Montermini, L ;
Lutz, Y ;
Cova, L ;
Hindelang, C ;
Jiralerspong, S ;
Trottier, Y ;
Kish, SJ ;
Faucheux, B ;
Trouillas, P ;
Authier, FJ ;
Durr, A ;
Mandel, JL ;
Vescovi, A ;
Pandolfo, M ;
Koenig, M .
HUMAN MOLECULAR GENETICS, 1997, 6 (11) :1771-1780
[6]   Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases [J].
Chong, ZZ ;
Kang, JQ ;
Maiese, K .
CIRCULATION, 2002, 106 (23) :2973-2979
[7]   Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades [J].
Digicaylioglu, M ;
Lipton, SA .
NATURE, 2001, 412 (6847) :641-647
[8]   Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage [J].
Grasso, G ;
Buemi, M ;
Alafaci, C ;
Sfacteria, A ;
Passalacqua, M ;
Sturiale, A ;
Calapai, G ;
De Vico, G ;
Piedimonte, G ;
Salpietro, FM ;
Tomasello, F .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (08) :5627-5631
[9]   FRIEDREICH ATAXIA - A CLINICAL AND GENETIC-STUDY OF 90 FAMILIES WITH AN ANALYSIS OF EARLY DIAGNOSTIC-CRITERIA AND INTRAFAMILIAL CLUSTERING OF CLINICAL-FEATURES [J].
HARDING, AE .
BRAIN, 1981, 104 (SEP) :589-620
[10]   Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage [J].
Juul, S .
ACTA PAEDIATRICA, 2002, 91 :36-42